COMMODORE CAPITAL LP's Net Worth
$212 Million
Who is COMMODORE CAPITAL LP?
COMMODORE CAPITAL LP has an estimated net worth of $212 Million. This is based on reported shares across multiple companies, which include Satsuma Pharmaceuticals, Inc., Vera Therapeutics, Inc., Vistagen Therapeutics, Inc., Enliven Therapeutics, Inc., and Ambrx Biopharma Inc..
SEC CIK
COMMODORE CAPITAL LP's CIK is 0001831942
Past Insider Trading and Trends
2021 was COMMODORE CAPITAL LP's most active year for acquiring shares with 18 total transactions. COMMODORE CAPITAL LP's most active month to acquire stocks was the month of September. 2022 was COMMODORE CAPITAL LP's most active year for disposing of shares, totalling 1 transactions. COMMODORE CAPITAL LP's most active month to dispose stocks was the month of October. 2023 saw COMMODORE CAPITAL LP paying a total of $24,937,303.77 for 7,859,188.75 shares, this is the most they've acquired in one year. In 2022 COMMODORE CAPITAL LP cashed out on 3,250,000 shares for a total of $2,294,500.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Satsuma Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -87.57% | -3.25M |
$0.71 | -$2,294,500.00 | 461.29K |
Nov 14
| |||
Form 4
| +0.08% | 2.92K |
$5.42 | $15,837.24 | 3.71M |
Nov 24
| |||
Form 4
| +0.36% | 13.2K |
$5.48 | $72,328.71 | 3.71M |
Nov 19 - Nov 22
| |||
Form 4
| +0.48% | 17.56K |
$5.94 | $104,331.75 | 3.7M |
Nov 10 - Nov 11
| |||
Form 4
| +0.02% | 560 |
$5.99 | $3,354.40 | 3.68M |
Nov 8
| |||
Form 4
| +0.25% | 9.2K |
$5.94 | $54,642.00 | 3.68M |
Nov 4 - Nov 5
| |||
Form 4
| +0.24% | 8.88K |
$5.64 | $50,083.20 | 3.67M |
Nov 2
| |||
Form 4
| +1.24% | 44.65K |
$5.71 | $254,957.21 | 3.66M |
Oct 29
| |||
Form 4
| +1.54% | 54.66K |
$5.48 | $299,421.55 | 3.61M |
Oct 27 - Oct 28
| |||
Form 4
| +1.73% | 60.45K |
$5.45 | $329,442.19 | 3.56M |
Oct 21 - Oct 22
| |||
Form 4
| +3.80% | 128.24K |
$5.19 | $665,237.32 | 3.5M |
Oct 19 - Oct 20
| |||
Form 4
| +5.05% | 162.19K |
$4.84 | $784,844.78 | 3.37M |
Oct 15 - Oct 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Vera Therapeutics, Inc. (VERA) Snapshot price: $37.935
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -19.27% | -1.05M |
$18.00 | -$18,900,000.00 | 4.4M |
Jan 10
| |||
Form 4
| +8.96% | 448.22K |
$15.17 | $6,799,003.67 | 5.45M |
Jun 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Vistagen Therapeutics, Inc. (VTGN) Snapshot price: $4.87
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 4
| |||
Form 4
| +97.06% | 775.76K |
$23.15 | $17,961,078.67 | 1.57M |
Aug 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Enliven Therapeutics, Inc. (ELVN) Snapshot price: $15.73
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +101.72% | 730.51K |
$22.07 |
—
| 1.45M |
Feb 23
| |||
Form 4
| +1.12% | 31.76K |
$5.15 | $163,498.15 | 2.87M |
Feb 21 - Feb 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ambrx Biopharma Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||